Dr. M. Michelle Berrey joined Chimerix in 2012 as Chief Medical Officer (CMO) and was named President and Chief Executive Officer (CEO) in April 2014. Prior to joining Chimerix, Dr. Berrey was CMO at Pharmasset, Inc., a company that focused on the development of nucleotide analogs for the treatment of hepatitis C, from 2007 until its acquisition by Gilead Sciences, Inc. (NASDAQ: GILD) in January 2012. Dr. Berrey's expertise includes the design, early development, medical governance, clinical strategy and product life cycle management of antiviral compounds. Previously, Dr. Berrey served as Vice President, Viral Diseases, Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline, where she was responsible for the early development of compounds for the treatment of HIV, hepatitis viruses and hepatic fibrosis. Dr. Berrey received her MD from the Medical College of Georgia and a Master of Public Health from Emory University. She completed her internship and residency in Internal Medicine at the University of North Carolina at Chapel Hill, and was a Senior Fellow in Infectious Diseases at the University of Washington, Seattle, where she conducted research in HIV transmission and acute HIV infection. She is Board Certified in Internal Medicine and Infectious Diseases.
Dr. Nichols joined Chimerix as Chief Medical Officer, in September 2014, from ViiV Healthcare, where he was the Head of Global Development; prior to his tenure at ViiV, Dr. Nichols spent ten years at GlaxoSmithKline leading multiple global antiviral programs in the United States and Europe, including the development and regulatory submissions to the FDA and EMA for the approval of Tivicay and the recent FDA approval of Triumeq. Dr. Nichols spent four years on the faculty of the Fred Hutchinson Cancer Research Center in Seattle, WA, where he was the principal investigator on NIH-funded grants exploring the prevention and treatment of CMV and respiratory virus infections in HCT recipients. Dr. Nichols received his M.D. from Duke University and earned an M.S. in Epidemiology from the University of Washington, where he completed a Fellowship in Infectious Diseases.
Mr. Trost joined Chimerix in 2011 as Senior Vice President and Chief Financial Officer, and had been working with Chimerix since 2010 in a consulting capacity related to the Series F financing and the BARDA contract. With more than 30 years of experience in the financial field, Mr. Trost last served as Vice President and CFO at Argos Therapeutics, Inc. (NASDAQ: ARGS), a venture-backed immunotherapy company located in Research Triangle Park. Previously, he was Senior Vice President and CFO at InteCardia, Inc., a venture-backed cardiac imaging company. While at InteCardia, Mr. Trost played a key role in negotiating and executing the sale of the company to Syncor International Corporation (NASDAQ: SCOR). Prior to InteCardia, Mr. Trost served as Executive Vice President and CFO of Coastal Physician Group, Inc. (NYSE: DR), a contract provider of emergency room physicians, having joined the company as Vice President of Corporate Development. Previously, he held the position of Vice President of Finance at Morganite North America. Mr. Trost began his professional career with PricewaterhouseCoopers LLP, spending time in four offices over 12 years, including an international assignment, and last served as a Senior Manager in the Research Triangle practice. Mr. Trost holds a BS in Accounting from the University of Illinois at Urbana-Champaign and is a Certified Public Accountant.
Ms. Richardson has over 25 years of pharmaceutical industry experience, with a strong background in launching new products and developing new therapeutic areas. Her category experience includes work in diabetes, anaphylaxis, cardiovascular, respiratory, lipids and neurology. Ms. Richardson joined Chimerix in January 2014 as Chief Commercial Officer, in charge of building and leading the organization’s commercial structure. Prior to that, Ms. Richardson was the Vice President and Head of the Global lixisenatide franchise, leading the commercial worldwide launch of Lyxumia. She also held the position of Vice President of Marketing at Reliant Pharmaceuticals, overseeing marketing and market research functions, including the successful launch of the first prescription omega-3 product, which helped lead to the company's acquisition by GlaxoSmithKline. Ms. Richardson held various positions of increasing responsibility at GlaxoSmithKline in the sales, market research, and marketing functions, working on several launches. Ms. Richardson served on the Board of Directors of Healthy Women, a non-profit organization dedicated to promoting health and wellness among women. In 2008, she was nominated by her peers as one of the "100 Most Inspiring Leaders" in the Life Sciences field and labeled as a "Market Maker" in PharmaVoice magazine, and in 2011 she was given the "Rising Star" award by the Healthcare Businesswomen's Association. She earned her BA in English at the University of Pennsylvania.
Dr. Rogers joined Chimerix in 2013 as Chief Development Officer. From 2007 to 2012, Dr. Rogers served as Chief Development Officer at Pharmasset, Inc., where his primary responsibility was to facilitate the design and implementation of development programs for hepatitis C antiviral compounds. From 2004 to 2007, Dr. Rogers served as Vice President, Division of Viral Diseases at GlaxoSmithKline, where he was responsible for antiviral discovery activities directed toward HIV and hepatitis C indications. From 2001 to 2004, Dr. Rogers served as Vice President, Antiviral Discovery Medicine at GlaxoSmithKline. Dr. Rogers has over 29 years of industry experience and has participated in all phases of antiviral and anti-infective drug development, including discovery, preclinical development, and Phase 1, 2, 3, and 3b/4 clinical development programs. Dr. Rogers received his PhD in medical parasitology and a Master of Public Health in medical microbiology from the University of North Carolina at Chapel Hill. He completed a postdoctoral fellowship in clinical microbiology at St. Jude Children’s Research Hospital in Memphis, Tennessee.
With over 20 years of global medical and clinical research experience in infectious and respiratory disease and clinical medicine, Dr. Momméja-Marin joined Chimerix as Vice President, Clinical Research in 2010. Most recently, he was Senior Medical Director, Infectious Diseases, for i3 Research Limited, a contract research organization, where he was the lead therapeutic expert in infectious diseases. His background includes numerous Phase 1 through Phase 4 clinical trials, including more than 25 late-stage trials, and interactions with regulatory Agencies worldwide. Previously, Dr. Momméja-Marin was Director of Clinical Research for Gilead Sciences, Inc., where he was responsible for the global development of hepatitis B and hepatitis C programs. He also held the positions of Clinical Research Physician at Triangle Pharmaceuticals and Physician of Internal Medicine and Infectious Diseases at Assistance Publique- Hôpitaux de Paris in France. Dr. Momméja-Marin received a medical degree from Paris VII University, France. He is certified in internal medicine and multiple subspecialties.
Dr. Alrutz joined Chimerix in 2012 and in September 2014 he was named Vice President, General Counsel. From 2002 to 2011, Dr. Alrutz was counsel to Trimeris, Inc. (NASDAQ: TRMS) serving in a variety of in-house positions, most recently as General Counsel. While at Trimeris, Dr. Alrutz had primary responsibility and oversight of the company’s legal department during the development and commercialization of FUZEON®, a first-in-class viral fusion inhibitor for the treatment of HIV. Dr. Alrutz received his JD from Duke University School of Law and his PhD in molecular biology from the Tufts University, Sackler School of Biomedical Sciences. He received his B.A. from the University of Pennsylvania
Mr. Guzman joined Chimerix as Vice President of Compliance in November 2014. He comes to Chimerix with a wide range of experience in legal, regulatory affairs, and Quality Assurance/Quality Control. He has been responsible for the implementation and management of GXP quality and regulatory systems for start-up companies, negotiation of critical MSAs, and management of PreApproval and GMP inspections by US FDA and international agencies such as China FDA, and European Medicines Agency (EMA) and has implemented programs on corporate ethics and grants management. Mr. Guzman most recently served as Corporate Regulatory Affairs Director at Smith and Nephew where he was responsible for global regulatory affairs and quality assurance. Mr. Guzman previously held positions in Regulatory and Quality Control at Cleveland Biolabs, Inc., Inspire Pharmaceuticals, Biomerieux North America, and Novartis-Ciba Vision Division. He received his JD from the Pontifical Catholic University of Puerto Rico, Master of Chemical and Life Sciences at the University of Maryland-College Park, MBA from the University of Massachusetts-Lowell, and a BS in Industrial Engineering at Polytechnic University.
Mr. Payne joined Chimerix as Senior Vice President of Business Development and Corporate Strategy in November 2014. He brings to Chimerix broad and significant experience in the pharmaceutical, diagnostics and contract research industries where he has held a number of senior management and business development positions in the United States and Europe. Mr Payne most recently served as a strategy consultant to Quantum Leap Healthcare, a California non-profit that has developed an innovative approach to accelerating the development and regulatory approval of new drugs for the treatment of breast cancer, and was co-founder and CEO of eXcelerate Research. Mr Payne previously served as Chief Business Officer at TcLand Expression, a molecular diagnostics company, and prior to that was Vice President, Corporate Development at Quintiles. He was the founder and Managing Director of the French affiliate of Innovex and has also held roles at Wellcome Research Labs, Sterling Drug and Glaxo. Mr Payne holds an Honors Degree in Pharmacology from the University of Manchester, UK and has completed post-graduate training at the University of North Carolina and the University of Chicago Graduate School of Business.